Reboxetine is a type of anti-depressant medicine known as a selective noradrenaline re-uptake inhibitor (SNRI). It works in a different way to most treatments for depression by preventing the re-absorption of a chemical called noradrenaline from nerve cells in the brain. This action prolongs the mood-lightening effect of Reboxetine and makes it an extremely efficient anxiety depression treatment.
Many treatments for depression have potential side effects, which older people are particularly susceptible to. Reboxetine is much better tolerated as an anti-depressant medicine and anxiety depression treatment, as it is a noradrenaline re-uptake inhibitor.
In studies, patients taking Reboxetine felt ‘much’ to ‘very much’ improved, and it was well tolerated by most. As a mood enhancement, its efficacy outweighed any Reboxetine side effects in 75% of patients. Overall, it has been found to be an effective and safe anti-depressant and mood enhancement.
Reboxetine is at the forefront of a new generation of anti-depressants called selective noradenaline re-uptake inhibitors. Unlike other treatments for depression, which focus on the chemical serotonin, Reboxetine increases the amount of noradrenaline in the brain.
Serotonin is a monoamine neurotransmitter, which controls mood, emotions, wakefulness, and temperature regulation. Too little serotonin results in people feeling depressed and drowsy.
Noradrenaline is a catecholamine, which acts as a hormone and a neurotransmitter. It is responsible for what is often referred to as the ‘fight or flight’ response. In times of stress, noradrenaline prepares your body for physical activity by increasing your heart rate and blood pressure, releasing glucose and increasing blood flow to your muscles. It also helps control wakefulness, arousal, mood, emotion and drive.
Whereas serotonin plays an important part in anxiety and mood, noradrenaline is essential for maintaining drive, self-assertiveness and the capacity for reward.
When depression occurs noradrenaline is decreased. A release of noradrenaline lightens mood. So when noradrenaline is reabsorbed into the nerve cells, it is no longer able to affect mood.
Reboxetine works by preventing this re-absorption of noradrenaline back into the nerve cells. When a neuron sends an electrical impulse, more noradrenaline is available, so a stronger message is passed, and activity in that area of the brain is increased.
Reboxetine works by prolonging the mood-lightening effect of noradrenaline and relieving depression.
Reboxetine tackles anxiety and stimulates the mind. It is an anti-depressant treatment that is particularly useful for older people suffering from low mood, sleep disturbances, low energy levels and poor concentration.
Reboxetine is thought to improve social behaviour, because noradrenaline is a chemical associated with increased social engagement and co-operation.
Reboxetine is not addictive and does not increase agitation, which is often exacerbated by other anti-depressant treatments. It is particularly effective in treating the symptoms of deficiencies in noradrenaline, such as impaired attention, concentration problems, fatigue and memory loss.
Reboxetine can also be used as a stimulant, and it has been shown to be effective in treating people with narcolepsy (uncontrolled daytime sleeping). Studies also suggest it may be useful in the treatment of panic disorder, Parkinson’s Disease and bulimia.
Reboxetine paved the way for clinical investigation into the role of the noradrenergic system in depressive disorders. Such was its success that by early 2007, it had been licensed for use in over 60 countries.
In short-term clinical trials of Reboxetine, researchers were able to demonstrate its effectiveness in treating major depression. In fact in a study of one group of severely depressed patients, Reboxetine proved significantly more effective than fluxotine.
In a longer term study, Reboxetine proved itself superior to the placebo in the prevention of relapse and recurrence of depression. The study reported that 78% of patients treated with Reboxteine were classed as in remission, compared to 45% in the placebo group.
The recommended starting dose for Reboxetine is 4mg twice daily, increasing to 10mg daily if necessary after 3 weeks. Older people should start at a dose of 2mg twice daily, increased to a maximum of 6mg daily if necessary after three weeks.
While doses may vary, Reboxetine’s effectiveness in tackling depression and anxiety is clear.
Like most anti-depressants, this drug could interfere with other anti-depressants, particularly MAO inhibitors (including Gerovital-H3) and also with noradrenaline enhancers, such as Adrafinil and Modafinil, and therefore any combined use must only take place under the guidance of a physician. Reboxetine reduce your ability to drive or operate machinery safely. Do not drive or operate machinery until you know how this medicine affects you and you are sure it won't affect your performance.